+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women



Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women



Journal of Cardiovascular Medicine 10(1): 85-92



Cardiovascular disease is the leading cause of death in women in Western countries. Despite preventive strategies, in the past decades the incidence of cardiovascular events has shown a decline in men but a rise in women, matching the growth of the population of postmenopausal women. Several epidemiological findings suggest the causative pathophysiological role of ovarian hormone deficiency in the development of cardiovascular disease in women. Observational and randomized studies have suggested that hormone replacement therapy in early postmenopause could be beneficial from a cardiovascular point of view. Conversely, aging, time since menopause and presence of cardiovascular risk factors or cardiovascular disease may decrease its efficacy and increase the risk of cardiovascular events. It is plausible that the unfavorable effects of the estrogen/progestin combination used in the randomized studies are not related to the hormone preparation per se but rather to the use of hormones in the less receptive group of women, older and with cardiovascular risk factors. Clinical judgment, choice of the right dose and estrogen/progestin combination are of pivotal importance to maximize the beneficial effect of estrogen replacement therapy/hormone replacement therapy, especially if given within a reasonable time after the menopause to women who need the therapy for the relief of menopausal symptoms.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053579613

Download citation: RISBibTeXText

PMID: 19145119

DOI: 10.2459/jcm.0b013e328313e979


Related references

Hormone replacement therapy does not prevent coronary heart disease and is associated with increased overall risk for health of postmenopausal women. Final results of studies on hormone replacement therapy efficacy in frame of Women's Health Initiative and data from other recent studies. Kardiologiia 43(9): 77-79, 2003

Hormone replacement therapy in postmenopausal women for cardioprotection. Journal of the Association of Physicians of India 46(3): 294-298, 1998

A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: consensus opinion of The North American Menopause Society. Menopause 7(2): 76-86, 2000

The latest elaboration of the Women's Health Initiative data on hormone replacement therapy and cardiovascular disease in postmenopausal women. Gynecological Endocrinology 23(4): 183-185, 2007

Study of tumor S-phase in postmenopausal women diagnosed with breast cancer while using hormone replacement therapy vs those never having used hormone replacement therapy. Proceedings of the American Association for Cancer Research Annual Meeting 37: 203, 1996

Lipid-mediated cardioprotection of long-term hormone replacement therapy in postmenopausal women. Clinical & Investigative Medicine 18(4 Suppl. ): B12, 1995

The relation between hormone replacement therapy and risk factors for cardiovascular disease in postmenopausal women. Maturitas 27(Suppl. ): 163, 1997

Hormone replacement therapy and cardiovascular disease: lessons from a monkey model of postmenopausal women. Ilar Journal 45(2): 139-146, 2004

Hormone replacement Up-to-date. Menopause in women and hormone replacement therapy (HRT). Indications for HRT in postmenopausal women. Clinical Calcium 17(9): 1315-1324, 2007

Is bio-identical hormone replacement therapy safer than traditional hormone replacement therapy?: a critical appraisal of cardiovascular risks in menopausal women. Treatments in Endocrinology 5(6): 367-374, 2006

Introduction: the role of hormone replacement therapy in prevention and treatment of cardiovascular disease in postmenopausal women. American Journal of Cardiology 89(12a): 1e-4e, 2002

The effect of hormone replacement therapy and exercise on cardiovascular disease risk factors in postmenopausal women. Sports Medicine 29(1): 39-49, 2000

Incidence of cardiovascular disease, cancer and death in postmenopausal women affirming use of hormone replacement therapy. Scandinavian Journal of Public Health 30(1): 12-19, 2002

Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. Gynecological Endocrinology 23(8): 436-444, 2007

Biological and practical aspects of hormone replacement therapy: an approach to cardiovascular disease prevention in postmenopausal women. Revista Portuguesa de Cardiologia 18(11): 1047-1055, 1999